BRPI0817334A8 - Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados - Google Patents

Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados

Info

Publication number
BRPI0817334A8
BRPI0817334A8 BRPI0817334A BRPI0817334A BRPI0817334A8 BR PI0817334 A8 BRPI0817334 A8 BR PI0817334A8 BR PI0817334 A BRPI0817334 A BR PI0817334A BR PI0817334 A BRPI0817334 A BR PI0817334A BR PI0817334 A8 BRPI0817334 A8 BR PI0817334A8
Authority
BR
Brazil
Prior art keywords
gallisepticum
bacteria
live attenuated
mycoplasma gallisepticum
composition
Prior art date
Application number
BRPI0817334A
Other languages
English (en)
Inventor
Kumar Mahesh
Ayub Khan Muhammad
Original Assignee
Wyeth Llc
Pah W Llc
Zoetis W Llc
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc, Pah W Llc, Zoetis W Llc, Zoetis Services Llc filed Critical Wyeth Llc
Publication of BRPI0817334A2 publication Critical patent/BRPI0817334A2/pt
Publication of BRPI0817334A8 publication Critical patent/BRPI0817334A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/35—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

BACTÉRIA MYCOPLASMA GALLISEPTICUM ATENUADAS VIVA, COMPOSIÇÃO PARA VACINA, USO DA DITA COMPOSIÇÃO E PROCESSO PARA IDENTIFICAÇÃO DE CLONES MYCOPLASMA GALLISEPTICUM ATENUADOS. A presente invenção refere-se a bactérias Mycoplasma gallisepticum atenuadas vivas que exibem expressão reduzida de uma proteína identificada como MGA_0621. Em certas modalidades, as bactérias atenuadas podem exibir adicionalmente a expressão reduzida de uma ou mais proteínas selecionadas do grupo que consiste em piruvato desidrogenase, fosfopiruvato hidratase, 2-desoxirribose-5-fosfato aldolase e proteína ribossomal L35, em relação a uma bactéria M. gallisepticum do tipo selvagem. São também fornecidas vacinas e processos de vacinação que envolvem o uso das bactérias M. gallisepticum atenuadas vivas e processos para a produção de bactérias M. gallisepticum atenuadas vivas. É fornecido um exemplo de cepa de M. gallisepticum atenuada viva, denominada MGx+47, que foi mostrada através de análise proteômica para exibir expressão significativamente reduzida de MGA_0621 e foi mostrado que era segura e eficaz quando administrada como uma vacina contra infecção por M. gallisepticum em frangos.
BRPI0817334A 2007-09-11 2008-09-10 Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados BRPI0817334A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99344707P 2007-09-11 2007-09-11
PCT/US2008/010630 WO2009035644A1 (en) 2007-09-11 2008-09-10 Attenuated mycoplasma gallisepticum strains

Publications (2)

Publication Number Publication Date
BRPI0817334A2 BRPI0817334A2 (pt) 2015-03-24
BRPI0817334A8 true BRPI0817334A8 (pt) 2016-03-29

Family

ID=40024216

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817334A BRPI0817334A8 (pt) 2007-09-11 2008-09-10 Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados

Country Status (22)

Country Link
US (4) US7935356B2 (pt)
EP (2) EP2564868A1 (pt)
JP (2) JP5451619B2 (pt)
KR (2) KR20120014041A (pt)
CN (1) CN101896195B (pt)
AR (1) AR068418A1 (pt)
AU (1) AU2008299913B2 (pt)
BR (1) BRPI0817334A8 (pt)
CA (1) CA2699410C (pt)
CL (1) CL2008002675A1 (pt)
CO (1) CO6260102A2 (pt)
ES (1) ES2437593T3 (pt)
HK (1) HK1145627A1 (pt)
ME (1) ME00982B (pt)
MX (1) MX2010002866A (pt)
NZ (1) NZ583829A (pt)
PL (1) PL2200640T3 (pt)
RU (1) RU2441909C2 (pt)
TW (1) TW200918666A (pt)
UA (1) UA98506C2 (pt)
WO (1) WO2009035644A1 (pt)
ZA (1) ZA201001740B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains
US20090068231A1 (en) * 2007-09-11 2009-03-12 Wyeth Live attenuated mycoplasma strains
UY32570A (es) * 2009-04-24 2010-11-30 Boehringer Ingelheim Vetmed Vacuna viva modificada de mycoplasma bovis mejorada
EP2571980A4 (en) * 2010-05-19 2014-02-26 Bioproperties Pty Ltd METHOD RELATED TO A WEAKEN MYCOPLASMA
CN102168073B (zh) * 2010-11-30 2013-03-20 瑞普（保定）生物药业有限公司 一种提高疫苗生产中鸡毒支原体增殖能力的方法
CN103074246B (zh) * 2012-08-31 2015-09-02 南京天邦生物科技有限公司 一种低血清高效培养鸡毒支原体弱毒株培养基及其制备方法
CN107446859B (zh) * 2017-09-02 2020-12-18 河南省农业科学院畜牧兽医研究所 一株鸡毒支原体及其应用
CN112159479B (zh) * 2020-10-15 2022-03-22 福建农林大学 一种鸡毒支原体多抗原表位融合蛋白pMG-mEA及其应用
CN114045298B (zh) * 2021-09-09 2023-10-20 武汉科前生物股份有限公司 一种鸡滑液囊支原体亚单位疫苗及制备方法及应用
CN114940955B (zh) * 2022-05-10 2023-08-11 兆丰华生物科技(南京)有限公司 一种鸡毒支原体弱毒疫苗株及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566833B1 (fr) * 1984-06-27 1986-11-14 Inst Francais Du Petrole Methode et perfectionnement aux outils de forage comportant des passages d'eau permettant une grande efficacite du nettoyage du front de taille
ES2058237T3 (es) * 1987-09-18 1994-11-01 Akzo Nv Metodo para la preparacion de una vacuna para combatir la infeccion mycoplasmica en aves de corral.
US6006134A (en) * 1998-04-30 1999-12-21 Medtronic, Inc. Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers
US7599736B2 (en) * 2001-07-23 2009-10-06 Dilorenzo Biomedical, Llc Method and apparatus for neuromodulation and physiologic modulation for the treatment of metabolic and neuropsychiatric disease
EP1063297B1 (en) * 1999-06-22 2008-12-17 Korea Kumho Petrochemical Co. Ltd. Farnesyl pyrophosphate synthase (FPS) derived from seedlings of sunflower (Helianthus annus)
JP4723707B2 (ja) * 1999-12-22 2011-07-13 パナソニック電工株式会社 痩身器具
US6885888B2 (en) * 2000-01-20 2005-04-26 The Cleveland Clinic Foundation Electrical stimulation of the sympathetic nerve chain
US6922590B1 (en) * 2000-11-21 2005-07-26 Advanced Bionics Corporation Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US20020187162A1 (en) * 2001-04-21 2002-12-12 Geary Steven J. Use of a live attenuated Mycoplasma gallisepticum strain as a vaccine and vector for the protection of chickens and turkeys from respiratory disease
US6721603B2 (en) * 2002-01-25 2004-04-13 Cyberonics, Inc. Nerve stimulation as a treatment for pain
US7239912B2 (en) * 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US7551964B2 (en) * 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7076292B2 (en) * 2002-04-25 2006-07-11 Medtronic, Inc. Optical communication of neurostimulation-system information
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
US7155278B2 (en) * 2003-04-21 2006-12-26 Medtronic, Inc. Neurostimulation to treat effects of sleep apnea
RU2420570C2 (ru) * 2003-07-25 2011-06-10 Бёрингер Ингельхайм Ветмедика, Инк. Lawsonia intracellularis ЕВРОПЕЙСКОГО ПРОИСХОЖДЕНИЯ И ВАКЦИНЫ, ДИАГНОСТИЧЕСКИЕ АГЕНТЫ НА ЕЕ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains

Also Published As

Publication number Publication date
AU2008299913B2 (en) 2014-05-08
EP2200640B1 (en) 2013-10-23
AU2008299913A1 (en) 2009-03-19
US7935356B2 (en) 2011-05-03
WO2009035644A1 (en) 2009-03-19
CN101896195B (zh) 2013-04-03
MX2010002866A (es) 2010-04-01
RU2010108641A (ru) 2011-10-20
ME00982B (me) 2011-04-30
HK1145627A1 (en) 2011-04-29
CA2699410A1 (en) 2009-03-19
US20130302373A1 (en) 2013-11-14
CL2008002675A1 (es) 2008-11-07
US20130022547A1 (en) 2013-01-24
UA98506C2 (en) 2012-05-25
KR101176717B1 (ko) 2012-09-03
PL2200640T3 (pl) 2014-02-28
JP2010538646A (ja) 2010-12-16
EP2200640A1 (en) 2010-06-30
US20090068232A1 (en) 2009-03-12
CA2699410C (en) 2013-08-20
ZA201001740B (en) 2014-03-26
CN101896195A (zh) 2010-11-24
NZ583829A (en) 2011-12-22
AR068418A1 (es) 2009-11-18
KR20100061526A (ko) 2010-06-07
US8298552B2 (en) 2012-10-30
RU2441909C2 (ru) 2012-02-10
BRPI0817334A2 (pt) 2015-03-24
CO6260102A2 (es) 2011-03-22
EP2564868A1 (en) 2013-03-06
JP2014027950A (ja) 2014-02-13
JP5451619B2 (ja) 2014-03-26
ES2437593T3 (es) 2014-01-13
US20110189099A1 (en) 2011-08-04
TW200918666A (en) 2009-05-01
KR20120014041A (ko) 2012-02-15

Similar Documents

Publication Publication Date Title
BRPI0817334A8 (pt) Bactéria mycoplasma gallisepticum atenuadas viva, composição para vacina, uso da dita composição e processo para identificação de clones mycoplasma gallisepticum atenuados
CO6460761A2 (es) Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
BR112015013700A8 (pt) composição, sequência nucleotídica, anticorpo sintético, e, uso da composição
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
AR068419A1 (es) Cepas de mycoplasma atenuadas vivas
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
MX362977B (es) Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente.
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112012028711A2 (pt) métodos para a fabricação de uma emulsão de óleo em água, para a preparação de um kit de vacina e para redestilação de uma composição compreendendo 99% de esqualeno ou mais, assim como emulsão de óleo em água e kit
BR112015031329A2 (pt) composições compreendendo ciclodextrina e ácido hialurônico reticulado
MX2010003719A (es) Vacuna de mycoplasma bovis y metodos de uso de la misma.
BR112015013004A2 (pt) molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
BR112017000445A2 (pt) compósito, processo para preparar um compósito, produto de consumo, usos de um compósito e de uma mescla, e, método para preparar um produto de lavanderia.
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
WO2012009774A3 (pt) Microrganismos recombinantes, métodos de preparação de linhagens vacinais, antígenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
BR112015015199A2 (pt) composição imunogênica compreendendo antígenos de micoplasma
BR112017004356A2 (pt) antígenos de streptococcus agalactiae associados a cepas virulentais em peixes
BR112023012529A2 (pt) Deleção genômica na vacina da peste suína africana que permite o crescimento eficiente em linhagens de células estáveis
BR112012029396A2 (pt) métodos relativos a um micoplasma atenuado.
BR112016006468A2 (pt) processo e composição de tratamento de um material vegetal

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PAH W LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS W LLC (US)

B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements